Published in Blood Weekly, November 6th, 1995
Oxygent (perflubron emulsion) is intended to reduce or eliminate the need for allogeneic (donor) blood during surgery. The current study is a randomized, controlled, efficacy trial involving surgical patients at multiple sites in the U.S. A similar study is expected to start in Europe shortly. Oxygent is being co-developed by Alliance and Ortho Biotech Inc. and The R.W. Johnson Pharmaceutical Research Institute, members of the Johnson & Johnson Family of Companies.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.